EP300 and prostate neoplasm: All this evidence indicates epigenetic writers as promising therapeutic targets, and several molecules targeting p300/CBP, PRMT5, EZH2 are being tested under clinical trials, alone or in combination with other therapies such as AR blockade or immunotherapy in advanced prostate tumours (Figure 1), which we summarize in Table 1 [16,77,78,79,80].